Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": Modifications in two large surveys between 2004 and 2006

Journal of Hepatology

Volumn 48, Issue 1, 2008, Pages 35-42

  Cacoub, Patrice ^a,b   Halfon, Philippe ^c   Rosenthal, Eric ^d   Pialoux, Gilles ^e   Benhamou, Yves ^b   Perronne, Christian ^f   Pol, Stanislas ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Laboratoire Alphabio   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e HÔPITAL TENON   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

^g Institut Cochin   (France)

Author keywords

HCV; HIV; Interferon; Treatment

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL PRACTICE; PHYSICIAN; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD4; ANTIVIRAL AGENTS; ATTITUDE OF HEALTH PERSONNEL; BIOPSY; FEMALE; FRANCE; GENOTYPE; HEALTH CARE SURVEYS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 36549007485     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.07.028     Document Type: Article

References (39)

1. Cacoub P., Geffray L., Rosenthal E., Perronne C., Veyssier P., Raguin G., et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis 32 (2001) 1207-1214
2. Rosenthal E., Poirée M., Pradier C., Perronne C., Salmon-Ceron D., Geffray L., et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17 (2003) 1803-1809
3. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
4. Jaggy C., von Overbeck J., Ledergerber B., Schwarz C., Egger M., Rickenbach M., et al. Mortality in the Swis Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet 362 (2003) 877-878
5. Tedaldi E.M., Baker R.K., Moorman A.C., Alzola C.F., Furhrer J., McCabe R.E., et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36 (2003) 363-367
6. Martin-Carbonero L., Soriano V., Valencia M.E., Lopez M., and Gonzalez-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses 17 (2001) 1467-1471
7. Lewden C., Salmon D., Morlat P., Bevilacqua S., Jougla E., Bonnet F., et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34 (2005) 121-130
8. Rosenthal E., Pialoux G., Bernard N., Pradier C., Rey D., Bentata M., et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group (MORTAVIC 2003 Study). J Viral Hepatol 14 (2007) 183-188
9. Sherman K.E., Rouster S.D., and Chung R.T. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 34 (2002) 831-837
10. Anonymous. Premiers résultats du nouveau dispositif de surveillance de l'infection à VIH et situation du sida au 30 September 2003. BEH 2004;24-25:102-109.
11. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
12. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
13. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499
14. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
15. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
16. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
17. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med 351 (2004) 451-459
18. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients. N Engl J Med 351 (2004) 438-450
19. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. A randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus standard interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in HIV-infected patients (RIBAVIC-ANRS HC02). JAMA 292 (2004) 2839-2848
20. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treatment of HIV-HCV co-infected patients. AIDS 18 (2004) F27-F36
21. Fleming C.A., Craven D.E., Thornton D., Tumilty S., and Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36 (2003) 97-100
22. Fleming C.A., Tumilty S., Murray J.E., and Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 40 (2005) S349-S354
23. Cacoub P., Rosenthal E., Halfon P., Sene D., Perronne C., and Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepatol 13 (2006) 678-682
24. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palu G., et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 (2005) 615-624
25. Maida I., Soriano V., Ramos B., Rios P., Gonzalez-Lahoz J., and Nunez M. Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center. HIV Clin Trials 6 (2005) 329-336
26. Mehta S.H., Lucas G.M., Mirel L.B., Torbenson M., Higgins Y., Moore R.D., et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 20 (2006) 2361-2369
27. Nunes D., Saitz R., Libman H., Cheng D.M., Vidaver J., and Samet J.H. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 30 (2006) 1520-1526
28. Cooper C.L., and Cameron D.W. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 41 (2005) S105-S109
29. Edlin B.R., Kresina T.F., Raymond D.B., Carden M.R., Gourevitch M.N., Rich J.D., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 40 (2005) S276-S285
30. Seydi M., Morlat P., Bonnet F., Rambeloarisoa J., Bernard N., Lacoste D., et al. Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up. Rev Med Intern 26 (2005) 280-287
31. Tien P.C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol 100 (2005) 2338-2354
32. Scheft H., and Fontenette D.C. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. Clin Infect Dis 40 (2005) S292-S296
33. Myers R.P., Benhamou Y., Imbert-Bismut F., Thibault V., Bochet M., Charlotte F., et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 17 (2003) 721-725
34. Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006) 1317-1325
35. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
36. Clanon K.A., Johannes Mueller J., and Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 40 (2005) S362-S366
37. Anonymous. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
38. Soriano V., Puoti M., Sulkowski M., Mauss S., Cacoub P., Cargnel A., et al. Care of patients with hepatitis C and HIV coinfection. AIDS 18 (2004) 1-12
39. Neff G.W., Shire N.J., and Rudich S.M. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. Clin Infect Dis 41 (2005) S50-S55